Authors: Namer, M Soler-Michel, P Turpin, F Chinet-Charrot, P de Gislain, C Pouillart, P Delozier, T Luporsi, E Etienne, PL Schraub, S Eymard, JC Serin, D Ganem, G Calais, G Maillart, P Colin, P Trillet-Lenoir, V Prevost, G Tigaud, D Clavere, P Marti, P Romieu, C Wendling, JL

Citation: M. Namer et al., Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer, EUR J CANC, 37(9), 2001, pp. 1132-1140

Authors: Thomas, X Cambier, N Taksin, AL Reman, O Vekhoff, A Pautas, C Leblond, V Soler-Michel, P Ecstein-Fraisse, E Archimbaud, E

Citation: X. Thomas et al., Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia, LEUK RES, 24(11), 2000, pp. 957-963

Authors: Philip, T Iliescu, C Demaille, MC Pacquement, H Gentet, JC Krakowski, I Soler-Michel, P Thiesse, P Chauvin, F Blay, JY Brunat-Mentigny, M

Citation: T. Philip et al., High-dose methotrexate and HELP [Holoxan (ifosfamide), Eldesine (vindesine), platinum] - doxorubicin in non-metastatic osteosarcoma of the extremity:A French multicentre pilot study, ANN ONCOL, 10(9), 1999, pp. 1065-1071